E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. Clinical response to treatment will be determined.

Trial Details

NCT ID
NCT05686226
Phase
PHASE2
Sponsor
Christian Hinrichs
Status
RECRUITING
Cancer Type
HPV Positive Head and Neck Cancer
Interventions
  • E7 TCR-T cells
  • Aldesleukin
Locations (sample)
  • Bethesda, Maryland, United States|38.98067,-77.10026
  • New Brunswick, New Jersey, United States|40.48622,-74.45182
  • New Brunswick, New Jersey, United States|40.48622,-74.45182

Key Eligibility Criteria

  • Histologically or cytologically confirmed metastatic or refractory/recurrent HPV-16+ cancer.
  • Tumor with HPV16 genotype as determined by testing performed in a CLIA certified laboratory.
  • HLA-A\*02:01 allele as determined by testing performed in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Participants ma…
  • Measurable disease as assessed by RECIST Criteria Version 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HPV Positive Head and Neck Cancer Trials on Trialify →